Cargando…
Biological Screening and Crystallographic Studies of Hydroxy γ-Lactone Derivatives to Investigate PPARγ Phosphorylation Inhibition
PPARγ represents a key target for the treatment of type 2 diabetes and metabolic syndrome. To avoid serious adverse effects related to the PPARγ agonism profile of traditional antidiabetic drugs, a new opportunity is represented by the development of molecules acting as inhibitors of PPARγ phosphory...
Autores principales: | Capelli, Davide, Cazzaniga, Giulia, Mori, Matteo, Laghezza, Antonio, Loiodice, Fulvio, Quaglia, Martina, Negro, Elisa, Meneghetti, Fiorella, Villa, Stefania, Montanari, Roberta |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10136296/ https://www.ncbi.nlm.nih.gov/pubmed/37189440 http://dx.doi.org/10.3390/biom13040694 |
Ejemplares similares
-
Screening of saponins and sapogenins from Medicago species as potential PPARγ agonists and X-ray structure of the complex PPARγ/caulophyllogenin
por: Montanari, Roberta, et al.
Publicado: (2016) -
Betulinic acid is a PPARγ antagonist that improves glucose uptake, promotes osteogenesis and inhibits adipogenesis
por: Brusotti, Gloria, et al.
Publicado: (2017) -
New γ-Halo-δ-lactones and δ-Hydroxy-γ-lactones with Strong Cytotoxic Activity
por: Kamizela, Angelika, et al.
Publicado: (2019) -
Structural basis for PPAR partial or full activation revealed by a novel ligand binding mode
por: Capelli, Davide, et al.
Publicado: (2016) -
Novel Benzylidene Thiazolidinedione Derivatives as Partial PPARγ Agonists and their Antidiabetic Effects on Type 2 Diabetes
por: Yasmin, Sabina, et al.
Publicado: (2017)